#Sintilimab plus #chemotherapy improved survival in ES‑SCLC, while #multiomics profiling revealed Tfh/T‑RM/B‑cell response signatures, #macrophage‑linked resistance, and a blood‑based #biomarker model for patient stratification.

#OpenAccess in #STTT: doi.org/10.1038/s413...

An open-label, single-arm, phase II #ClinicalTrial assessing the efficacy of #Sintilimab + #Anlotinib revealed promising #AntiTumor effect and safety profile in treatment-naïve #Metastatic #ColorectalCancer (mCRC) patients.

#OpenAccess: doi.org/10.1038/s413...

An open-label, single-arm, phase II #ClinicalTrial of #Sintilimab + #Anlotinib in treatment-naïve #Metastatic #ColorectalCancer patients showed promising #Antitumor efficacy & a tolerable safety profile.

#STTT #OpenAccess: doi.org/10.1038/s413...

Immune checkpoint inhibitor-associated hypothyroidism, macular rash and adrenal insufficiency: case report and review of the literature A complex case of hypothyroidism, macular rash, and adrenal insufficiency that developed in an older man several months after he received sintilimab for the treatment of esophageal carcinoma.

#MedCase - Delve into this complex case of #hypothyroidism, macular rash, and adrenal insufficiency that developed in an older man several months after he received #sintilimab for the treatment of esophageal carcinoma.

👉 buff.ly/x70oebs

#EndoSky #OncSky

Scientists report that #sintilimab plus #anlotinib demonstrates promising efficacy and manageable safety in treatment-naïve #mCRC, achieving an ORR of 48.3%, DCR of 89.7%, median PFS of 8.6 months, and OS of 22.9 months. #medsky

#FeaturedArticle in #STTT: doi.org/10.1038/s413...

First-line #sintilimab plus #platinum-etoposide is effective and safe in #ESSCLC, with multi-omics analyses revealing local and systemic #ImmuneLandscapes, enabling the construction of a non-invasive #biomarker model. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

First-line #sintilimab plus #platinum-etoposide is effective and safe in #ESSCLC, with multi-omics analyses revealing local and systemic #ImmuneLandscapes, enabling the construction of a non-invasive #biomarker model. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

This phase II trial demonstrated that #sintilimab plus #anlotinib exhibited preliminary #antitumor efficacy & a manageable safety profile as a #chemotherapy-free approach in treatment-naïve #MetastaticColorectalCancer. #medsky

Read in #STTT #OpenAccess: doi.org/10.1038/s413...

Joint NDA Acceptance for Sintilimab and Fruquintinib in Chinese Renal Cell Carcinoma Treatment Innovent and HUTCHMED have announced the acceptance of a New Drug Application in China for a combination therapy aimed at advanced renal cell carcinoma, marking a significant milestone in treatment options.

Joint NDA Acceptance for Sintilimab and Fruquintinib in Chinese Renal Cell Carcinoma Treatment #China #Suzhou #renal_cancer #Sintilimab #Fruquintinib

Innovent and HUTCHMED Achieve Milestone in Kidney Cancer Treatment with Promising Study Results Innovent Biologics and HUTCHMED's latest study shows promising results for treating advanced renal cell carcinoma, meeting crucial clinical endpoints.

Innovent and HUTCHMED Achieve Milestone in Kidney Cancer Treatment with Promising Study Results #China #Suzhou #Innovent #Sintilimab #HUTCHMED

Innovent's Novel CTLA-4 Inhibitor Gains Priority Review for Colon Cancer Treatment in China Innovent Biologics receives a Priority Review from China's NMPA for ipilimumab injection as a neoadjuvant therapy in colon cancer treatment, marking a significant milestone.

Innovent's Novel CTLA-4 Inhibitor Gains Priority Review for Colon Cancer Treatment in China #China #Suzhou #Innovent_Biologics #Ipilimumab #Sintilimab